Mirvetuximab Soravtansine Efficacy in Platinum-Resistant Ovarian Cancer

Introduction to Mirvetuximab Soravtansine

The American Society of Clinical Oncology recommends considering mirvetuximab soravtansine for patients with platinum-resistant ovarian cancer, as it has shown significant benefits in progression-free survival and overall survival, with a median overall survival of 16.46 months, according to the American College of Obstetricians and Gynecologists 1

Inhibitors of PARP, such as olaparib, niraparib, and rucaparib, have demonstrated benefits primarily in patients with BRCA mutations or homologous recombination deficiency (HRD), with an overall response rate of 42.3% for mirvetuximab soravtansine, as stated by the National Comprehensive Cancer Network 2
Mirvetuximab soravtansine offers an important alternative for patients with high FRα expression, regardless of BRCA mutation status, with a hazard ratio of 0.67 for overall survival, according to the European Society for Medical Oncology 3